More recently, Glenmark Pharmaceuticals Ltd. reported that GRC 17536, a peripheral acting TRPA1 antagonist, exhibited efficacy in a phase 2a proof-of-concept study in patients with painful diabetic neuropathy. This evidence concerns the gene TRPA1 and diabetic neuropathy.